Important Safety Information
Toujeo is contraindicated during episodes of hypoglycemia and in patients allergic to insulin glargine or any of its excipients.
Bạn đang đọc: Toujeo® (insulin glargine injection) 300 Units/mL
Warnings and Precautions
Toujeo contains the lapp active component, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per milliliter .
Insulin pens and needles must never be shared between patients. Do NOT reuse needles.
Monitor lineage glucose in all patients treated with insulin. Modify insulin regimens only under medical supervision. Changes in insulin regimen, force, manufacturer, type, injection site or method acting of administration may result in the necessitate for a change in insulin drug or an alteration in accompaniment oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia .
Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia ; sudden change in the injection locate ( to unaffected area ) has been reported to result in hypoglycemia. rede patients to rotate injection locate to unaffected areas and closely proctor for hypoglycemia .
whole for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another radical insulin to Toujeo, patients experienced higher median fast plasma glucose levels in the first few weeks of therapy until titrated to their individualize fast plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control alike to Lantus .
hypoglycemia is the most park adverse reaction of insulin therapy, including Toujeo, and may be dangerous .
medicine errors, such as accidental mix-ups between basal insulin products and other insulins, peculiarly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection .
Do not dilute or mix Toujeo with any other insulin or solution. If shuffle or diluted, the solution may become cloudy, and the attack of action/time to peak effect may be altered in an irregular manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.
severe dangerous, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated .
A decrease in the Toujeo dose may be required in patients with nephritic or liverwort deterioration .
As with all insulins, Toujeo use can lead to dangerous hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular cardiac arrhythmia, and death. closely monitor potassium levels in patients at gamble of hypokalemia and treat if indicated .
Fluid retention, which may lead to or exacerbate heart bankruptcy, can occur with attendant function of thiazolidinediones ( TZDs ) with insulin. These patients should be observed for signs and symptoms of heart failure. If affection failure occurs, dosage reduction or discontinuance of TZD must be considered .
Certain drugs may affect glucose metabolism, requiring insulin drug adjustment and close monitoring of rake glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs ( for example, beta-blockers, clonidine, guanethidine, and reserpine ) .
adverse reactions normally associated with Toujeo include hypoglycemia, allergic reactions, injection locate reactions, lipodystrophy, pruritus, rash, edema and weight gain.
Important Safety Information for Toujeo SoloStar® and Toujeo Max SoloStar®
Toujeo SoloStar and Toujeo Max SoloStar are single-patient-use prefilled insulin pens. To help ensure an accurate dose each meter, patients should follow all steps in the Instruction Leaflet accompanying the pen ; otherwise they may not get the correct total of insulin, which may affect their blood glucose levels. It is specially authoritative to perform a safety test when a affected role is using a newly pen for the first meter .
Do not withdraw Toujeo from the SoloStar and Max SoloStar single-patient-use prefilled pens with a syringe .
All registered trademarks cited are property of their respective owners .